How to decide between Ibrutinib and Idelalisib-Rituximab  in relapse setting

How to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting

ScrippsHealth

4 years
594 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Susan M. O'Brien, MD of University of California Irvine discusses how to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer
Up Next Autoplay